Oruka Therapeutics Inc
ORKA
NASDAQ
Biotechnology
$111.04
USD
+2.92 (+2.70%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $7.11B
Volume 1.0M
Revenue
$0
TTM
— YoY
Gross Margin
—
TTM
— YoY
Net Income
$-132.89M
TTM
— YoY
Operating Cash Flow
$-100.92M
TTM
— YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
YoY Growth | — | — | — | — | — |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Selling, General & Administrative | 4.3 | 5.1 | 6.8 | 7.3 | 6.9 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 28.4 | 34.1 | 34.4 | 36.4 | 50.1 |
Operating Income | -28.4 | -34.1 | -34.4 | -36.4 | -50.1 |
EBITDA | -28.4 | -34.1 | -34.4 | -36.4 | -50.1 |
Other Income / Expense | -0.0 | -0.0 | -0.0 | 0.0 | 0.0 |
Total Other Income / Expense | 3.9 | 3.8 | 4.8 | 4.6 | 8.9 |
Income Before Income Taxes | -24.6 | -30.3 | -29.6 | -31.8 | -41.2 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -24.6 | -30.3 | -29.6 | -31.8 | -41.2 |
Consolidated Net Income / Loss | -24.6 | -30.3 | -29.6 | -31.8 | -41.2 |
Net Income Attributable to Common Shareholders | -19.3 | -24.0 | -24.5 | -31.8 | -34.9 |
Basic EPS | -$0.46 | -$0.55 | -$0.44 | -$0.48 | -$0.55 |
Diluted EPS | -$0.46 | -$0.55 | -$0.44 | -$0.48 | -$0.55 |
Basic Shares Outstanding | 42.1M | 44.1M | 55.2M | 55.2M | 62.9M |
Diluted Shares Outstanding | 42.1M | 44.1M | 55.2M | 55.2M | 62.9M |